TScan Therapeutics Inc
For the period ended Mar 31, 2024. Filed May 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 13, 2024
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Non-voting Common Stock · Paid-In · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balances at January 1, 2023 | 19,082,820 | $2 | 5,143,134 | $1 | $257,810 | $(158,379) | $99,434 |
| Conversion of non-voting common stock to voting common stock | 397,909 | - | (397,909) | - | - | - | - |
| Stock-based compensation expense | - | - | - | - | 1,147 | - | 1,147 |
| Net loss | - | - | - | - | - | (22,563) | (22,563) |
| Balances at March 31, 2023 | 19,480,729 | $2 | 4,745,225 | $1 | $258,957 | $(180,942) | $78,018 |
| Balances at January 1, 2024 | 43,552,941 | $4 | 4,276,588 | $1 | $398,459 | $(247,597) | $150,867 |
| Exercise of stock options | 75,208 | - | - | - | 258 | - | 258 |
| Stock-based compensation expense | - | - | - | - | 1,984 | - | 1,984 |
| Net loss | - | - | - | - | - | (30,142) | (30,142) |
| Balances at March 31, 2024 | 43,628,149 | $4 | 4,276,588 | $1 | $400,701 | $(277,739) | $122,967 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.